Pipeline

OKYO is focused on the development of OK-101 to treat ocular diseases, including dry eye, uveitis, allergic conjunctivitis and ocular pain. The main focus of the company is clinical development of OK-101 to treat dry eye disease (DED).

A Focus on Ocular Therapies

Pipeline

AssetIndicationPre-ClinicalIND-Enabling StudiesPhase 1Phase 2Phase 3
OK-101
Dry Eye

Neuropathic Corneal Pain

Allergic Conjunctivitis

Uveitis

OK-201
Discovery Program

DrugIndicationStage
OK-101
Dry EyePhase 2*
Neuropathic Corneal PainIND-Enabling Studies
Allergic ConjunctivitisPre-Clinical
UveitisPre-Clinical
OK-201
Discovery Program

OK-101 Development Timeline

  • Skipping Phase 1
  • Designing Phase 2 effectively as a Phase 3 registration trial